Viewing Study NCT07241403

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 7:39 PM

Ignite Modification Date: 2025-12-25 @ 5:19 PM

Study NCT ID: NCT07241403

Status: COMPLETED

Last Update Posted: 2025-11-21

First Post: 2025-07-25

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)

Sponsor: Second Affiliated Hospital of Nanchang University

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module